England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

The treatment of life-threatening viruses not addressed with approved therapies. The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications.

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

The UK's National Health Service has introduced a quick injection method for administering the cancer drug Nivolumab, significantly reducing treatment time and hospital stays.

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

F indings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated formula and delivery, NeoVax MI ,is not only feasible ...